AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Edward Boghosian who wrote (1634)	9/1/1999 11:51:00 AM
From: Doorman	Read Replies (1) of 2173

> But -are these results significantly more positive than before? Absolutely, Edward. The previous Ph 3 trial results for Type 2 were ambiguous. The Type 1 results have been consistently more promising. So the statistically significant data for Type 2 is huge and welcome news - remember Type 2 is a much bigger market than Type 1. <<What are the chances of being blindsided from subsequent results? I don't see how unless they analyzed the data incorrectly. There are no more Ph 3 trials out there for Type 2 for AMLN. This was it. <From the results so far, is this company SIGNIFICANTLY closer to a marketable drug then we were about a year ago? Yes. They are preparing their submission now. I contacted their CEO, Joe Cook, and he informed me they will wait for the Type 1 data to be analyzed and made public before submitting an NDA. AMLN wants to submit the data for both Type 1 and 2 at the same time. The Type 1 data should be available in the 4th quarter. Another significant aspect of yesterday's news is that AMLN can leverage much better terms for a marketing partner. Also, they are a much more attractive take-over candidate. Good luck, Doorman

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next